Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission

Franca Fagioli, Marco Zecca, Franco Locatelli, Edoardo Lanino, Cornelio Uderzo, Paolo Di Bartolomeo, J. Massimo Berger, Claudio Favre, Roberto Rondelli, Andrea Pession, Chiara Messina

Research output: Contribution to journalArticle

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for patients with relapsed acute myeloid leukemia. In this retrospective, multicenter study, we analyzed the outcome of 63 children (median age, 7 y; range, 0.2 to 17) who received unmanipulated allo-HSCT in second complete remission. Either a matched family donor or an unrelated donor was used in 29 (46%) and 34 (54%) patients, respectively. The stem cell source was bone marrow in 53 children (84%), peripheral blood in 7 (11%), and cord blood in 3 patients (5%). Preparative regimen included total body irradiation in 25 patients (40%). The 5-year estimates of overall survival and leukemia-free survival were 53% [95% confidence interval (CI) 39-66] and 49% (95% CI 35-63), respectively, whereas the cumulative incidence of relapse and transplantrelated mortality (TRM) were 26% (95% CI 16-41) and 25% (95% CI 15-40), respectively. In multivariate analysis, the use of a matched family donor predicted a better probability of LFS [relative risk (RR) 2.29, P=0.05]. Both chronic graft-versushost disease occurrence and age at diagnosis greater than 11 years were associated with an increased TRM (RR 8.08, P=0.04 and RR 4.38, P=0.05, respectively). These results indicate that allo-HSCT is a procedure able to rescue a significant proportion of children with acute myeloid leukemia in second complete remission, especially if an human leukocyte antigen-compatible relative is employed as donor. Both leukemia recurrence and TRM contributed to treatment failure. Optimization of donor selection and of strategies for both prophylaxis and treatment of graft-versus-host disease may improve the results of unrelated donor allo-HSCT.

Original languageEnglish
Pages (from-to)575-583
Number of pages9
JournalJournal of Pediatric Hematology/Oncology
Volume30
Issue number8
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Acute Myeloid Leukemia
Confidence Intervals
Unrelated Donors
Tissue Donors
Mortality
Leukemia
Donor Selection
Recurrence
Survival
Whole-Body Irradiation
Graft vs Host Disease
HLA Antigens
Treatment Failure
Fetal Blood
Multicenter Studies
Stem Cells
Multivariate Analysis
Retrospective Studies

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • AML in second CR
  • Leukemia relapse
  • Pediatric patients

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology
  • Medicine(all)

Cite this

Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission. / Fagioli, Franca; Zecca, Marco; Locatelli, Franco; Lanino, Edoardo; Uderzo, Cornelio; Di Bartolomeo, Paolo; Berger, J. Massimo; Favre, Claudio; Rondelli, Roberto; Pession, Andrea; Messina, Chiara.

In: Journal of Pediatric Hematology/Oncology, Vol. 30, No. 8, 08.2008, p. 575-583.

Research output: Contribution to journalArticle

Fagioli, Franca ; Zecca, Marco ; Locatelli, Franco ; Lanino, Edoardo ; Uderzo, Cornelio ; Di Bartolomeo, Paolo ; Berger, J. Massimo ; Favre, Claudio ; Rondelli, Roberto ; Pession, Andrea ; Messina, Chiara. / Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission. In: Journal of Pediatric Hematology/Oncology. 2008 ; Vol. 30, No. 8. pp. 575-583.
@article{346e36abce8546a2888188eea37609b5,
title = "Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission",
abstract = "Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for patients with relapsed acute myeloid leukemia. In this retrospective, multicenter study, we analyzed the outcome of 63 children (median age, 7 y; range, 0.2 to 17) who received unmanipulated allo-HSCT in second complete remission. Either a matched family donor or an unrelated donor was used in 29 (46{\%}) and 34 (54{\%}) patients, respectively. The stem cell source was bone marrow in 53 children (84{\%}), peripheral blood in 7 (11{\%}), and cord blood in 3 patients (5{\%}). Preparative regimen included total body irradiation in 25 patients (40{\%}). The 5-year estimates of overall survival and leukemia-free survival were 53{\%} [95{\%} confidence interval (CI) 39-66] and 49{\%} (95{\%} CI 35-63), respectively, whereas the cumulative incidence of relapse and transplantrelated mortality (TRM) were 26{\%} (95{\%} CI 16-41) and 25{\%} (95{\%} CI 15-40), respectively. In multivariate analysis, the use of a matched family donor predicted a better probability of LFS [relative risk (RR) 2.29, P=0.05]. Both chronic graft-versushost disease occurrence and age at diagnosis greater than 11 years were associated with an increased TRM (RR 8.08, P=0.04 and RR 4.38, P=0.05, respectively). These results indicate that allo-HSCT is a procedure able to rescue a significant proportion of children with acute myeloid leukemia in second complete remission, especially if an human leukocyte antigen-compatible relative is employed as donor. Both leukemia recurrence and TRM contributed to treatment failure. Optimization of donor selection and of strategies for both prophylaxis and treatment of graft-versus-host disease may improve the results of unrelated donor allo-HSCT.",
keywords = "Allogeneic hematopoietic stem cell transplantation, AML in second CR, Leukemia relapse, Pediatric patients",
author = "Franca Fagioli and Marco Zecca and Franco Locatelli and Edoardo Lanino and Cornelio Uderzo and {Di Bartolomeo}, Paolo and Berger, {J. Massimo} and Claudio Favre and Roberto Rondelli and Andrea Pession and Chiara Messina",
year = "2008",
month = "8",
doi = "10.1097/MPH.0b013e31816e2342",
language = "English",
volume = "30",
pages = "575--583",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission

AU - Fagioli, Franca

AU - Zecca, Marco

AU - Locatelli, Franco

AU - Lanino, Edoardo

AU - Uderzo, Cornelio

AU - Di Bartolomeo, Paolo

AU - Berger, J. Massimo

AU - Favre, Claudio

AU - Rondelli, Roberto

AU - Pession, Andrea

AU - Messina, Chiara

PY - 2008/8

Y1 - 2008/8

N2 - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for patients with relapsed acute myeloid leukemia. In this retrospective, multicenter study, we analyzed the outcome of 63 children (median age, 7 y; range, 0.2 to 17) who received unmanipulated allo-HSCT in second complete remission. Either a matched family donor or an unrelated donor was used in 29 (46%) and 34 (54%) patients, respectively. The stem cell source was bone marrow in 53 children (84%), peripheral blood in 7 (11%), and cord blood in 3 patients (5%). Preparative regimen included total body irradiation in 25 patients (40%). The 5-year estimates of overall survival and leukemia-free survival were 53% [95% confidence interval (CI) 39-66] and 49% (95% CI 35-63), respectively, whereas the cumulative incidence of relapse and transplantrelated mortality (TRM) were 26% (95% CI 16-41) and 25% (95% CI 15-40), respectively. In multivariate analysis, the use of a matched family donor predicted a better probability of LFS [relative risk (RR) 2.29, P=0.05]. Both chronic graft-versushost disease occurrence and age at diagnosis greater than 11 years were associated with an increased TRM (RR 8.08, P=0.04 and RR 4.38, P=0.05, respectively). These results indicate that allo-HSCT is a procedure able to rescue a significant proportion of children with acute myeloid leukemia in second complete remission, especially if an human leukocyte antigen-compatible relative is employed as donor. Both leukemia recurrence and TRM contributed to treatment failure. Optimization of donor selection and of strategies for both prophylaxis and treatment of graft-versus-host disease may improve the results of unrelated donor allo-HSCT.

AB - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for patients with relapsed acute myeloid leukemia. In this retrospective, multicenter study, we analyzed the outcome of 63 children (median age, 7 y; range, 0.2 to 17) who received unmanipulated allo-HSCT in second complete remission. Either a matched family donor or an unrelated donor was used in 29 (46%) and 34 (54%) patients, respectively. The stem cell source was bone marrow in 53 children (84%), peripheral blood in 7 (11%), and cord blood in 3 patients (5%). Preparative regimen included total body irradiation in 25 patients (40%). The 5-year estimates of overall survival and leukemia-free survival were 53% [95% confidence interval (CI) 39-66] and 49% (95% CI 35-63), respectively, whereas the cumulative incidence of relapse and transplantrelated mortality (TRM) were 26% (95% CI 16-41) and 25% (95% CI 15-40), respectively. In multivariate analysis, the use of a matched family donor predicted a better probability of LFS [relative risk (RR) 2.29, P=0.05]. Both chronic graft-versushost disease occurrence and age at diagnosis greater than 11 years were associated with an increased TRM (RR 8.08, P=0.04 and RR 4.38, P=0.05, respectively). These results indicate that allo-HSCT is a procedure able to rescue a significant proportion of children with acute myeloid leukemia in second complete remission, especially if an human leukocyte antigen-compatible relative is employed as donor. Both leukemia recurrence and TRM contributed to treatment failure. Optimization of donor selection and of strategies for both prophylaxis and treatment of graft-versus-host disease may improve the results of unrelated donor allo-HSCT.

KW - Allogeneic hematopoietic stem cell transplantation

KW - AML in second CR

KW - Leukemia relapse

KW - Pediatric patients

UR - http://www.scopus.com/inward/record.url?scp=53749093669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53749093669&partnerID=8YFLogxK

U2 - 10.1097/MPH.0b013e31816e2342

DO - 10.1097/MPH.0b013e31816e2342

M3 - Article

C2 - 18799933

AN - SCOPUS:53749093669

VL - 30

SP - 575

EP - 583

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 8

ER -